Compare NEULAND LABS with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS TORRENT PHARMA NEULAND LABS/
TORRENT PHARMA
 
P/E (TTM) x 45.4 35.1 129.4% View Chart
P/BV x 3.4 8.9 38.7% View Chart
Dividend Yield % 0.1 0.7 15.3%  

Financials

 NEULAND LABS   TORRENT PHARMA
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
TORRENT PHARMA
Mar-19
NEULAND LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7541,964 38.4%   
Low Rs2471,245 19.9%   
Sales per share (Unadj.) Rs594.5453.4 131.1%  
Earnings per share (Unadj.) Rs12.625.8 49.0%  
Cash flow per share (Unadj.) Rs37.062.3 59.4%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.41.1 37.7%  
Book value per share (Unadj.) Rs553.4279.2 198.2%  
Shares outstanding (eoy) m12.83169.22 7.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.83.5 23.8%   
Avg P/E ratio x39.662.2 63.7%  
P/CF ratio (eoy) x13.525.8 52.5%  
Price / Book Value ratio x0.95.7 15.7%  
Dividend payout %15.865.9 24.0%   
Avg Mkt Cap Rs m6,421271,513 2.4%   
No. of employees `0001.313.6 9.4%   
Total wages/salary Rs m1,23614,038 8.8%   
Avg. sales/employee Rs Th5,949.45,642.6 105.4%   
Avg. wages/employee Rs Th963.81,032.4 93.4%   
Avg. net profit/employee Rs Th126.4320.9 39.4%   
INCOME DATA
Net Sales Rs m7,62776,728 9.9%  
Other income Rs m39571 6.8%   
Total revenues Rs m7,66677,299 9.9%   
Gross profit Rs m1,01919,831 5.1%  
Depreciation Rs m3136,177 5.1%   
Interest Rs m2165,038 4.3%   
Profit before tax Rs m5299,187 5.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m3671,254 29.3%   
Profit after tax Rs m1624,363 3.7%  
Gross profit margin %13.425.8 51.7%  
Effective tax rate %69.413.6 508.4%   
Net profit margin %2.15.7 37.4%  
BALANCE SHEET DATA
Current assets Rs m5,15250,375 10.2%   
Current liabilities Rs m3,57651,653 6.9%   
Net working cap to sales %20.7-1.7 -1,240.4%  
Current ratio x1.41.0 147.7%  
Inventory Days Days10592 114.1%  
Debtors Days Days9168 133.1%  
Net fixed assets Rs m3,96983,648 4.7%   
Share capital Rs m129846 15.2%   
"Free" reserves Rs m6,97146,397 15.0%   
Net worth Rs m7,10047,244 15.0%   
Long term debt Rs m77439,129 2.0%   
Total assets Rs m12,310141,209 8.7%  
Interest coverage x3.52.8 122.3%   
Debt to equity ratio x0.10.8 13.2%  
Sales to assets ratio x0.60.5 114.0%   
Return on assets %3.16.7 46.1%  
Return on equity %2.39.2 24.7%  
Return on capital %9.512.3 76.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,18722,103 23.5%   
Fx outflow Rs m1,5935,522 28.8%   
Net fx Rs m3,59416,581 21.7%   
CASH FLOW
From Operations Rs m57317,981 3.2%  
From Investments Rs m-487-2,413 20.2%  
From Financial Activity Rs m-55-13,145 0.4%  
Net Cashflow Rs m332,380 1.4%  

Share Holding

Indian Promoters % 36.3 71.5 50.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 63.7 7.0 907.8%  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 8.8 724.2%  
Shareholders   12,705 26,511 47.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   ALEMBIC  AUROBINDO PHARMA  IPCA LABS  FDC  SUN PHARMA  

Compare NEULAND LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat, GAIL and UPL Among Top Nifty Gainers(Closing)

Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Mar 8, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS - FULFORD INDIA COMPARISON

COMPARE NEULAND LABS WITH

MARKET STATS